|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02181 MABPHARM-B
Nominal 
0.330 -0.005 (-1.493%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 108,483 | 146.440% | 87,161 | 55,918 | 82,882 | 0 |
| Cost of Sales | (14,127) | 127.928% | (11,923) | (15,375) | (16,777) | -- |
| Gross Profit | 94,356 | 149.474% | 75,238 | 40,543 | 66,105 | -- |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (756) | 18.310% | (427) | (118) | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (97,569) | -2.430% | (209,356) | (210,819) | (291,744) | (184,632) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (97,569) | -2.430% | (209,356) | (210,819) | (291,744) | (184,632) | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 5,203 | 16.190% | 9,427 | 6,806 | 449 | (5,516) |
| Depreciation & Amortisation | 31,172 | 12.583% | 60,695 | 51,549 | 43,877 | 24,397 |
| Directors' Emoluments | -- | -- | 11,447 | 7,878 | 10,309 | 12,913 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -2.000 | 0.000% | -5.000 | -5.000 | -7.000 | -4.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.014 | (0.014) | (0.048) | (0.036) |
| NBV per share ($) | 0.028 | -- | 0.050 | 0.097 | 0.146 | 0.214 |
| Remarks: | Real time quote last updated: 13/11/2024 16:04 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -97,569,000 |
| %Change | -2.430% |
| EPS / (LPS) | RMB -0.020 |
| NBV Per Share (¥) | RMB 0.028 |